Clinical Trial Update: Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10 [Phase 1]

View source ↗

Summary

Phase 1 single and multiple ascending dose study assessing safety, tolerability, PK and PD of AG10 in transthyretin amyloid cardiomyopathy; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• AG10

Snippet

Sponsor: Eidos Therapeutics, a BridgeBio company | Conditions: Amyloid Cardiomyopathy, Transthyretin-Related | Phase 1 | Status: COMPLETED